TRK-IN-18

TRK-IN-18

• CAS Number: 2412008-91-2
• UNSPSC Description: TRK-IN-18 is a potent inhibitor of TRK. Tropomyosin-related kinases (Trks) are a family of receptor tyrosine kinases activated by neurotrophins, a group of soluble growth factors including Nerve Growth Factor (NGF), Brain-Derived Neurotrophic Factor (BDNF) and Neurotrophin-3 (NT-3) and Neurotrophin-4/5 (NT-4/5). TRK-IN-18 has the potential for the research of cancer diseases (extracted from patent WO2021148805A1, compound 7)[1].
• Target Antigen: Trk Receptor
• Type: Reference compound
• Related Pathways: Neuronal Signaling;Protein Tyrosine Kinase/RTK
• Applications: Cancer-Kinase/protease
• Field of Research: Cancer
• Assay Protocol: https://www.medchemexpress.com/trk-in-18.html
• Solubility: 10 mM in DMSO
• Smiles: CSC1=C(C=C(C=C1)F)[C@H]2C[C@@H](CN2C3=NN4C(C(NCC5=CC(O)=CC=C5)=O)=CN=C4C=C3)F
• Molecular Weight: 495.54
• References & Citations: [1]Nicola ROBAS, et al. Topical pharmaceutical compositions comprising imidazo[1,2-b]pyridazine compounds. Paatent WO2021148805A1.
• Shipping Conditions: Room temperature
• Clinical Information: No Development Reported